#United States #New York #healthcare technology #DarioHealth #Q2 2026

DarioHealth Financial Highlights for Q2 2026

DarioHealth Corp., a leader in AI-driven healthcare technology, has made headlines with its financial announcement for the second quarter of 2026, which wraps up a transformative period of growth and strategic repositioning. The company reported revenues of $5.2 million, showing a slight decline from $5.6 million in the previous quarter but demonstrating resilience as it strategically transitions away from certain pharmaceutical business lines.

Commercial Success

Despite these changes, DarioHealth's gross margin saw a notable increase to 62%, up from 57% in Q1 2026 and 55% a year earlier. The company celebrated a significant uptick in its multi-condition strategy, which contributed over 80% of the annual recurring revenue (ARR) totaling $13.1 million. This strong performance reflects Dario's effective partnerships and expanding client base.

Dario's CEO, Erez Raphael, articulated optimism, stating, "We believe Dario has reached a pivotal stage where our investments in technology and infrastructure are yielding positive momentum. Our multi-condition platform, backed by robust clinical evidence, has become increasingly appealing to clients. We're excited about provider-backed care as a vital extension of our services, giving us access to a larger share of the healthcare value chain."

The company has secured three major contracts recently, including a partnership with a top-five national health plan, enhancing Dario's revenue potential significantly. This latest achievement underpins its land-and-expand strategy, reflecting confidence among existing clients who are adding more conditions to their service agreement with Dario, which operates across various chronic conditions.

Financial Performance Overview

For the second quarter of 2026, DarioHealth reported:

• - Revenue: $5.2 million
• - Gross Profit: $3.2 million
• - Operating Expenses: $9.7 million
• - Operating Loss: $6.5 million, a 30% improvement from the previous year
• - Net Loss: $7.9 million, a notable decrease from $13 million reported in Q2 2025.

Year-over-year, operating expenses decreased by 21%, reflecting Dario's focus on cost efficiency while navigating investments in growth. This trajectory is coupled with a pro forma cash balance of $36.8 million after securing $22.8 million in net proceeds through direct financing, bolstering the company’s financial stability.

Looking Ahead

DarioHealth's stability is underscored by its pioneering offerings aimed at enhanced chronic care, including tools catering to perimenopause and sleep apnea, further expanding its market reach. The company's commitment to integrating technology within its experience promises notable growth opportunities. As more health plans embrace these services, DarioHealth is ideally positioned to capitalize on the growing healthcare demands of an aging population.

Conclusion

DarioHealth’s latest financial results highlight the company’s strategic shift and adaptation in the healthcare technology landscape, focusing on efficiency and growth in chronic condition management. With various successful partnerships on the horizon and ongoing investment in AI-powered solutions, DarioHealth is set not just to recover but also to thrive in an evolving market. Investors, healthcare planners, and industry stakeholders will be watching closely as DarioHealth continues its journey toward redefining chronic healthcare management.

The company's next conference call is scheduled for August 11, 2026, at 8:30 AM ET, where more insights into ongoing strategies and performance metrics will be shared.